ahh, Zacks' research report is worth as much as its price.

How is Tolero deal any significant other than getting a dormant pipeline drug moving. It is already said that the short term money for that deal is neglegible.

It offers no longer term perspective. Why is it not part of their calculation of future income in determing the price target?